Beone Medicines Ltd. current report, 01 April 2018

Business Context and Reporting Period

This Form 8-K Current Report was filed by BeiGene, Ltd. on April 4, 2018, covering events that occurred on April 1, 2018. The filing addresses corporate governance changes, specifically the appointment of a new director and the restoration of compliance with NASDAQ listing rules regarding the Audit Committee.

Key Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and director compensation arrangements.

Material Changes

  • Board Appointment: Jing-Shyh (Sam) Su was appointed to the Board of Directors to fill a vacancy. He serves as a Class I director until the 2020 Annual General Meeting.
  • Committee Compliance: Timothy Chen, an existing independent director, was appointed to the Audit Committee. This action restored the company's compliance with NASDAQ Listing Rule 5605, which requires a minimum of three audit committee members.

Guidance, Outlook, and Management Commentary

The filing provides no financial guidance, outlook, or management commentary regarding business operations or risks. It details the qualifications of the new director, Mr. Su, highlighting his 26-year tenure at Yum! Brands, Inc., where he led the China division, and his expertise in marketing and international business development.

Compensation Arrangements:

  • Equity: Mr. Su was granted a share option to purchase 63,290 ordinary shares. The exercise price is set at 1/13 of the closing price of the company's ADSs on April 2, 2018. The option vests ratably over three years.
  • Cash: Mr. Su will receive annual cash compensation of $45,000 plus reimbursement for reasonable travel and expenses.
  • Future Grants: He is entitled to annual equity grants in accordance with the company's independent director compensation policy.

Investor Verification Checklist

  • Verify the closing price of BeiGene's ADSs on April 2, 2018, to calculate the specific exercise price of Mr. Su's share option.
  • Review the company's Proxy Statement on Schedule 14A (filed April 26, 2017) for details on the standard compensation and indemnification for independent directors.
  • Confirm the current composition of the Audit Committee to ensure ongoing compliance with NASDAQ Listing Rule 5605.
  • Check the 2016 Share Option and Incentive Plan to understand the annual limits on director compensation that influenced the size of the initial option grant.